Dennis M. Brown - Jan 5, 2023 Form 4 Insider Report for Kintara Therapeutics, Inc. (KTRA)

Role: Chief Scientific Officer
Signature: /s/ Anthony Scott Praill, attorney-in-fact for Dennis M. Brown
Stock symbol: KTRA
Transactions as of: Jan 5, 2023
Transactions value $: $0
Form type: 4
Date filed: 1/6/2023, 06:26 PM
Previous filing: Aug 3, 2022
Next filing: Sep 1, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KTRA	Common Stock, par value $0.001 per share	Will/Inheritance	$0	+363	+7.35%	$0.00	5.3K	Jan 5, 2023	Direct	F1
holding	KTRA	Common Stock, par value $0.001 per share						1.08K	Jan 5, 2023	See footnote	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 4,801 restricted stock units that are unvested.
F2	Shares held by Valent Technologies LLC, of which the Reporting Person is the sole member and owner and holds sole voting and dispositive power over its shares.

Remarks:

The shares reported on this Form 4 have been adjusted to reflect the Issuer's 1-for-50 reverse stock split of its common stock, effective November 11, 2022.